Comparison
21 Hydroxylase Deficient Congenital Adrenal Hyperplasia C2936858 vs 16q24 3 Microdeletion Syndrome C4304594
Clinical comparison between 21 Hydroxylase Deficient Congenital Adrenal Hyperplasia and 16q24 3 Microdeletion Syndrome for differential diagnosis and treatment planning.
21 Hydroxylase Deficient Congenital Adrenal Hyperplasia C2936858
An inherited disorder affecting adrenal hormone production, causing cortisol deficiency and other hormonal imbalances. Features may include ambiguous genitalia, salt-wasting crises, and growth issues. Treated with lifelong hormone replacement therapy.
16q24 3 Microdeletion Syndrome C4304594
A genetic condition resulting from deletion of a small segment on chromosome 16. Affected individuals may have developmental delays and physical differences. Care is individualized based on specific needs.
6 comparison axes
Onset
21 Hydroxylase Deficient Congenital Adrenal Hyperplasia C2936858
0-null
16q24 3 Microdeletion Syndrome C4304594
0-null
Onset patterns differ
Severity
21 Hydroxylase Deficient Congenital Adrenal Hyperplasia C2936858
severe
16q24 3 Microdeletion Syndrome C4304594
moderate
Different severity levels
Chronic
21 Hydroxylase Deficient Congenital Adrenal Hyperplasia C2936858
Chronic
16q24 3 Microdeletion Syndrome C4304594
Chronic
Differing course
Communicable
21 Hydroxylase Deficient Congenital Adrenal Hyperplasia C2936858
No
16q24 3 Microdeletion Syndrome C4304594
No
Different transmission
Body System
21 Hydroxylase Deficient Congenital Adrenal Hyperplasia C2936858
endocrine
16q24 3 Microdeletion Syndrome C4304594
congenital
Same/different system
Category
21 Hydroxylase Deficient Congenital Adrenal Hyperplasia C2936858
endocrine
16q24 3 Microdeletion Syndrome C4304594
genetic
Different category
Bottom line
21-hydroxylase-deficient-congenital-adrenal-hyperplasia-C2936858 and 16q24-3-microdeletion-syndrome-C4304594 differ in severity, etiology
Key differentiating points
Findings that most reliably separate the two conditions at the bedside or in the workup.
| Feature | 21 Hydroxylase Deficient Congenital Adrenal Hyperplasia C2936858 | 16q24 3 Microdeletion Syndrome C4304594 | Discriminating power |
|---|---|---|---|
| Adrenal or salt-wasting crisis | May cause cortisol deficiency and salt-wasting crisis. | Not described as a typical feature in the supplied source. | High |
| Development | Growth issues may occur; developmental delay is not the defining feature. | Developmental delay may be present. | Moderate |
| Physical differences | Ambiguous genitalia may occur in some affected infants. | Physical differences may occur; specific genital findings are not established. | Moderate |
When to favor each condition
Choose 21 Hydroxylase Deficient Congenital Adrenal Hyperplasia C2936858 when
Suspected adrenal insufficiency or salt-wasting
The source links this condition to cortisol deficiency and possible crises.
High
Ambiguous genitalia with endocrine concern
This presentation is described for 21-hydroxylase-deficient CAH, not the deletion.
Moderate
Planning lifelong hormone replacement
The supplied description specifies lifelong hormone replacement therapy.
High
Choose 16q24 3 Microdeletion Syndrome C4304594 when
Confirmed small deletion at 16q24.3
The diagnosis is defined by chromosomal deletion rather than adrenal biochemistry.
High
Developmental delay with congenital differences
These are the principal features stated in the source.
Moderate
Need for individualized supportive care
Care is described as tailored to specific developmental and physical needs.
Moderate
How key tests differ
| Test | 21 Hydroxylase Deficient Congenital Adrenal Hyperplasia C2936858 | 16q24 3 Microdeletion Syndrome C4304594 | Interpretation |
|---|---|---|---|
| Adrenal steroid or cortisol evaluation | May support cortisol deficiency; exact cutoffs are not supplied. | No characteristic adrenal result is established. | Abnormal results require clinician interpretation and do not alone prove either diagnosis. |
| Electrolytes | Salt-wasting may disturb sodium and potassium balance. | No characteristic electrolyte pattern is described. | Electrolyte changes are findings, not a diagnosis. |
| Chromosomal microarray | Not the defining test in the supplied description. | May identify the 16q24.3 microdeletion. | Genetic confirmation should be interpreted by a qualified clinician. |
Prognosis comparison
21 Hydroxylase Deficient Congenital Adrenal Hyperplasia C2936858
- Outcome
- Chronic endocrine condition; exact survival or complication rates are not supplied.
- Factors
- Crisis prevention, hormone management, and growth monitoring may influence course.
16q24 3 Microdeletion Syndrome C4304594
- Outcome
- Chronic congenital condition with variable needs; prognosis is not quantified here.
- Factors
- Developmental profile and associated physical differences may shape support needs.
Time frame: Both are described as chronic; precise onset is not established.
Early recognition and clinician-directed care are relevant, but outcomes cannot be predicted from these data.
Complications comparison
| Complication | Presentation |
|---|---|
| Acute hormonal crisis | Salt-wasting crisis is a described risk. Not established from the supplied description. Suspected crisis needs urgent clinical assessment. |
| Growth or physical concerns | Growth issues and genital differences may occur. Physical differences may occur, but details are unspecified. Findings vary and should not be assumed identical. |
| Developmental needs | Not described as the primary complication. Developmental delay may require ongoing support. Support needs are individualized. |
Patient education highlights
- HighEmergency recognition
For CAH, seek urgent care for suspected salt-wasting or adrenal crisis. This is not established for the microdeletion.
- HighDifferent causes
One is an adrenal hormone disorder; the other is a chromosomal deletion. Neither is communicable.
- MediumFollow-up
CAH may need lifelong hormone therapy; microdeletion care depends on individual developmental and physical needs.